Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 12/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311870 | 0.87 | NPBWR1 (0.63) | NPBWR1MCHR1ALDH1A1PKMPKLR | |
| SCHEMBL4178254 | 0.87 | ALDH1A1 (0.61) | NPBWR1ALDH1A1PKMHTTHSD17B10 | |
| SCHEMBL25756148 | 0.86 | NPBWR1 (0.61) | NPBWR1MCHR1ALDH1A1PKMPKLR | |
| SCHEMBL30277194 | 0.85 | NPBWR1 (0.60) | NPBWR1MCHR1PKMPKLRHTT | |
| SCHEMBL14844510 | 0.84 | NPBWR1 (0.67) | NPBWR1MCHR1ALDH1A1PKMPKLR | |
| SCHEMBL23304878 | 0.84 | NPBWR1 (0.51) | NPBWR1MCHR1ALDH1A1PKMPKLR | |
| SCHEMBL23304874 | 0.84 | NPBWR1 (0.51) | NPBWR1MCHR1ALDH1A1PKMPKLR | |
| SCHEMBL26915060 | 0.83 | NPBWR1 (0.61) | NPBWR1MCHR1ALDH1A1PKMPKLR | |
| SCHEMBL31016909 | 0.82 | NPBWR1 (0.52) | NPBWR1MCHR1ALDH1A1SMN1; SMN2CMA1 | |
| SCHEMBL23535857 | 0.82 | NPBWR1 (0.67) | NPBWR1MCHR1PKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12371421-B2 | Solid forms of a PARP7 inhibitor | RIBON THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250074897-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024149234-A1 | PARP7 INHIBITORS AND USES THEREOF | Angel Pharmaceutical Co., Ltd. (CN) | 2024-07-18 | — | — | WO | disclosed |
| US-20240190844-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-118126063-A | Pyridazinone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118027039-A | Crystal of substituted piperazine derivative and preparation method thereof | 成都百裕制药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117986255-A | Pyridazinone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020223229-A1 | SOLID FORMS OF A PARP7 INHIBITOR | RIBON THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-20240190844-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-12371421-B2 | Solid forms of a PARP7 inhibitor | PARP1, PARP2, PARP4 | NPBWR1 4489/4885MCHR1 4866/4885ALDH1A1 992/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-20250074897-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | NPBWR1 2135/4885MCHR1 4315/4885ALDH1A1 686/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885ALDH1A1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.